StockTipsArenaBeta

BUY Lupin Limited — Aditya Agarwal, Coheron Brokers

BUYLupin Limited
Lupin share price target & all analyst calls

byAditya Agarwal, Coheron BrokersHorizon: NA (inferred 1–3 months)21 Sept 2026via Business Today

Entry₹2,117.6Inferred
Target₹2,300
Total upside +8.61%
Stop lossNot given
CMP₹1,988.11d ago
Active-6.12%+15.69%upside left 6 wk left
Follow Aditya Agarwal for new calls(45% target hit, 20 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 2 other Short-term calls on LUPINSee 74 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:24 pm IST
16 supporting4 neutral7 opposing
Supports the BUY call (16)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

11 advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · adjacent horizon·5 Nov · 2d ago

Lupin launches HIV drug in US, secures eligibility for 180-day generic exclusivity

NewsCnbc-Tv18·3 Nov · 3d ago

(opens in new tab)

Lupin has launched Raltegravir Tablets (600 mg) in the United States market.

BSE · Company Update·3 Nov · 3d ago

(opens in new tab)

Lupin gets USFDA nod for amifampridine tablets, eligible for 180-day generic exclusivity

NewsCnbc-Tv18·2 Nov · 4d ago

(opens in new tab)
Neutral / worth noting (4)

Lupin shares in focus after US sales beat expectations but profitability impacted

NewsCnbc-Tv18·4 Nov · 3d ago

(opens in new tab)

Lupin Ltd reported unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

BSE · Board Meeting·4 Nov · 3d ago

(opens in new tab)

Lupin Limited reported its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

NSE · Outcome of Board Meeting·4 Nov · 3d ago

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3w ago

(opens in new tab)
Weighs against the BUY call (7)

Broker’s Call: Lupin (Accumulate)

NewsHbl·5 Nov · yesterday

(opens in new tab)

Lupin Q2 Review: Jefferies Cuts Target 15%, Flags US Competition; Kotak Retains Add

NewsNdtv-Profit·5 Nov · 2d ago

(opens in new tab)

Lupin reported Q2 FY2027 results with a 21.8% YoY decline in profit for the period to INR 11,553 Mn and a 10.7% decline in EBITDA to INR 21,712 Mn.

BSE · Company Update·4 Nov · 3d ago

(opens in new tab)

Lupin Limited reported Q2 FY2027 financial results showing a 22.2% year-on-year decline in Profit After Tax (PAT) to INR 11,553 million and a 10.7% decline in EBITDA.

NSE · Press Release·4 Nov · 3d ago

(opens in new tab)

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·27 Aug · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Aditya Agarwal, Coheron Brokers

Every call and its outcome